Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer
Introduction The bone scan index (BSI) was introduced as a quantitative tool for tumor involvement in bone of patients with metastatic prostate cancer (mPCa). The computer-aided diagnosis device for BSI analysis EXINIbone BSI seems to represent technical progress for the quantitative assessment of b...
Gespeichert in:
| Veröffentlicht in: | Advances in therapy 2017-04, Vol.34 (4), p.986-994 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 994 |
|---|---|
| container_issue | 4 |
| container_start_page | 986 |
| container_title | Advances in therapy |
| container_volume | 34 |
| creator | Haupt, Fabian Berding, Georg Namazian, Ali Wilke, Florian Böker, Alena Merseburger, Axel Geworski, Lilli Kuczyk, Markus Antonius Bengel, Frank Michael Peters, Inga |
| description | Introduction
The bone scan index (BSI) was introduced as a quantitative tool for tumor involvement in bone of patients with metastatic prostate cancer (mPCa). The computer-aided diagnosis device for BSI analysis EXINIbone
BSI
seems to represent technical progress for the quantitative assessment of bone involvement. But it is not yet clear if the automated BSI (aBSI) could contribute to improved evaluation of progression in patients under antiandrogens or chemotherapy in contrast to the visual interpretation and/or conventional biomarkers such as the prostate-specific antigen (PSA).
Methods
In 49 mPCa patients, bone scans were performed initially and during different therapy courses. Scans were evaluated visually and by the artificial-neural-network-based expert system EXINIbone
BSI
. Progression of metastatic bone involvement was defined according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria in the visual interpretation. The computer-assisted interpretation was based on different cutoff values in relative changes of the aBSI. Additionally, assessments according to bone scanning were compared to changes in the PSA value as a potential surrogate for treatment response.
Results
Using a sensitive cutoff value (5% or 10%) for the relative aBSI increase led to significantly increased progression determination compared to the visual interpretation of bone scans (49% and 43% vs. 27%,
p
|
| doi_str_mv | 10.1007/s12325-017-0505-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1875142223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1875142223</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-98937aaabcbf767efe90a4ca11010bc11c29e3deb470602338955047711676963</originalsourceid><addsrcrecordid>eNp9kDFPwzAQhS0EoqXwA1hQRpbAnRPHyQhVgUpFIAESm-WYS9WqcYqdIOivx1GAkcG68_l9T-fH2CnCBQLIS4884SIGlDEIEPFuj40xz0QcDt9nY5ApxjzJX0fsyPs1AAcp8kM24jnPRI44ZvXsc0uujZ6-fEt1VDUuum4sRU9G22huW3JbR61uV0241lvXfJCPHl2zdOR9P7zyPnQ12TZa2YG9D4DvGdMr-46iqbaG3DE7qPTG08lPnbCXm9nz9C5ePNzOp1eL2KQIbVzkRSK11qUpK5lJqqgAnRqNCAilQTS8oOSNylRCBjxJ8kIISKVEzGRWZMmEnQ--YeH3jnyr6pU3tNloS03nFeZSYMp5QCcMB6kJq3pHldq6Va3dl0JQfcpqSFmFlFWfstoF5uzHvitrevsjfmMNAj4IfHiyS3Jq3XTOhi__4_oN59WI9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1875142223</pqid></control><display><type>article</type><title>Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Haupt, Fabian ; Berding, Georg ; Namazian, Ali ; Wilke, Florian ; Böker, Alena ; Merseburger, Axel ; Geworski, Lilli ; Kuczyk, Markus Antonius ; Bengel, Frank Michael ; Peters, Inga</creator><creatorcontrib>Haupt, Fabian ; Berding, Georg ; Namazian, Ali ; Wilke, Florian ; Böker, Alena ; Merseburger, Axel ; Geworski, Lilli ; Kuczyk, Markus Antonius ; Bengel, Frank Michael ; Peters, Inga</creatorcontrib><description>Introduction
The bone scan index (BSI) was introduced as a quantitative tool for tumor involvement in bone of patients with metastatic prostate cancer (mPCa). The computer-aided diagnosis device for BSI analysis EXINIbone
BSI
seems to represent technical progress for the quantitative assessment of bone involvement. But it is not yet clear if the automated BSI (aBSI) could contribute to improved evaluation of progression in patients under antiandrogens or chemotherapy in contrast to the visual interpretation and/or conventional biomarkers such as the prostate-specific antigen (PSA).
Methods
In 49 mPCa patients, bone scans were performed initially and during different therapy courses. Scans were evaluated visually and by the artificial-neural-network-based expert system EXINIbone
BSI
. Progression of metastatic bone involvement was defined according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria in the visual interpretation. The computer-assisted interpretation was based on different cutoff values in relative changes of the aBSI. Additionally, assessments according to bone scanning were compared to changes in the PSA value as a potential surrogate for treatment response.
Results
Using a sensitive cutoff value (5% or 10%) for the relative aBSI increase led to significantly increased progression determination compared to the visual interpretation of bone scans (49% and 43% vs. 27%,
p
< 0.001). In 63% of the cases PSA and BSI changes matched, whereas in 18% progression was only indicated by the aBSI. A relative cutoff of 5% for the aBSI decrease could reclassify 47 serial scan pairs which were visually interpreted as stable into 22 progressive and 25 remissive scans.
Conclusion
Distinct thresholds of the relative aBSI could help to better assess disease progression in mPCa patients. Manual corrections of the BSI values are not required in most cases. The aBSI could serve as a useful additional parameter for therapy monitoring in mPCa patients in the future.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-017-0505-z</identifier><identifier>PMID: 28265811</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Aged ; Bone Neoplasms - diagnostic imaging ; Bone Neoplasms - secondary ; Cardiology ; Disease Progression ; Endocrinology ; Expert Systems ; Health technology assessment ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Research ; Pharmacology/Toxicology ; Prognosis ; Prostatic Neoplasms - pathology ; Radionuclide Imaging ; Retrospective Studies ; Rheumatology</subject><ispartof>Advances in therapy, 2017-04, Vol.34 (4), p.986-994</ispartof><rights>Springer Healthcare 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-98937aaabcbf767efe90a4ca11010bc11c29e3deb470602338955047711676963</citedby><cites>FETCH-LOGICAL-c410t-98937aaabcbf767efe90a4ca11010bc11c29e3deb470602338955047711676963</cites><orcidid>0000-0002-2401-922X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-017-0505-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-017-0505-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28265811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haupt, Fabian</creatorcontrib><creatorcontrib>Berding, Georg</creatorcontrib><creatorcontrib>Namazian, Ali</creatorcontrib><creatorcontrib>Wilke, Florian</creatorcontrib><creatorcontrib>Böker, Alena</creatorcontrib><creatorcontrib>Merseburger, Axel</creatorcontrib><creatorcontrib>Geworski, Lilli</creatorcontrib><creatorcontrib>Kuczyk, Markus Antonius</creatorcontrib><creatorcontrib>Bengel, Frank Michael</creatorcontrib><creatorcontrib>Peters, Inga</creatorcontrib><title>Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><addtitle>Adv Ther</addtitle><description>Introduction
The bone scan index (BSI) was introduced as a quantitative tool for tumor involvement in bone of patients with metastatic prostate cancer (mPCa). The computer-aided diagnosis device for BSI analysis EXINIbone
BSI
seems to represent technical progress for the quantitative assessment of bone involvement. But it is not yet clear if the automated BSI (aBSI) could contribute to improved evaluation of progression in patients under antiandrogens or chemotherapy in contrast to the visual interpretation and/or conventional biomarkers such as the prostate-specific antigen (PSA).
Methods
In 49 mPCa patients, bone scans were performed initially and during different therapy courses. Scans were evaluated visually and by the artificial-neural-network-based expert system EXINIbone
BSI
. Progression of metastatic bone involvement was defined according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria in the visual interpretation. The computer-assisted interpretation was based on different cutoff values in relative changes of the aBSI. Additionally, assessments according to bone scanning were compared to changes in the PSA value as a potential surrogate for treatment response.
Results
Using a sensitive cutoff value (5% or 10%) for the relative aBSI increase led to significantly increased progression determination compared to the visual interpretation of bone scans (49% and 43% vs. 27%,
p
< 0.001). In 63% of the cases PSA and BSI changes matched, whereas in 18% progression was only indicated by the aBSI. A relative cutoff of 5% for the aBSI decrease could reclassify 47 serial scan pairs which were visually interpreted as stable into 22 progressive and 25 remissive scans.
Conclusion
Distinct thresholds of the relative aBSI could help to better assess disease progression in mPCa patients. Manual corrections of the BSI values are not required in most cases. The aBSI could serve as a useful additional parameter for therapy monitoring in mPCa patients in the future.</description><subject>Aged</subject><subject>Bone Neoplasms - diagnostic imaging</subject><subject>Bone Neoplasms - secondary</subject><subject>Cardiology</subject><subject>Disease Progression</subject><subject>Endocrinology</subject><subject>Expert Systems</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Research</subject><subject>Pharmacology/Toxicology</subject><subject>Prognosis</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Radionuclide Imaging</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDFPwzAQhS0EoqXwA1hQRpbAnRPHyQhVgUpFIAESm-WYS9WqcYqdIOivx1GAkcG68_l9T-fH2CnCBQLIS4884SIGlDEIEPFuj40xz0QcDt9nY5ApxjzJX0fsyPs1AAcp8kM24jnPRI44ZvXsc0uujZ6-fEt1VDUuum4sRU9G22huW3JbR61uV0241lvXfJCPHl2zdOR9P7zyPnQ12TZa2YG9D4DvGdMr-46iqbaG3DE7qPTG08lPnbCXm9nz9C5ePNzOp1eL2KQIbVzkRSK11qUpK5lJqqgAnRqNCAilQTS8oOSNylRCBjxJ8kIISKVEzGRWZMmEnQ--YeH3jnyr6pU3tNloS03nFeZSYMp5QCcMB6kJq3pHldq6Va3dl0JQfcpqSFmFlFWfstoF5uzHvitrevsjfmMNAj4IfHiyS3Jq3XTOhi__4_oN59WI9w</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Haupt, Fabian</creator><creator>Berding, Georg</creator><creator>Namazian, Ali</creator><creator>Wilke, Florian</creator><creator>Böker, Alena</creator><creator>Merseburger, Axel</creator><creator>Geworski, Lilli</creator><creator>Kuczyk, Markus Antonius</creator><creator>Bengel, Frank Michael</creator><creator>Peters, Inga</creator><general>Springer Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2401-922X</orcidid></search><sort><creationdate>20170401</creationdate><title>Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer</title><author>Haupt, Fabian ; Berding, Georg ; Namazian, Ali ; Wilke, Florian ; Böker, Alena ; Merseburger, Axel ; Geworski, Lilli ; Kuczyk, Markus Antonius ; Bengel, Frank Michael ; Peters, Inga</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-98937aaabcbf767efe90a4ca11010bc11c29e3deb470602338955047711676963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Bone Neoplasms - diagnostic imaging</topic><topic>Bone Neoplasms - secondary</topic><topic>Cardiology</topic><topic>Disease Progression</topic><topic>Endocrinology</topic><topic>Expert Systems</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Research</topic><topic>Pharmacology/Toxicology</topic><topic>Prognosis</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Radionuclide Imaging</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haupt, Fabian</creatorcontrib><creatorcontrib>Berding, Georg</creatorcontrib><creatorcontrib>Namazian, Ali</creatorcontrib><creatorcontrib>Wilke, Florian</creatorcontrib><creatorcontrib>Böker, Alena</creatorcontrib><creatorcontrib>Merseburger, Axel</creatorcontrib><creatorcontrib>Geworski, Lilli</creatorcontrib><creatorcontrib>Kuczyk, Markus Antonius</creatorcontrib><creatorcontrib>Bengel, Frank Michael</creatorcontrib><creatorcontrib>Peters, Inga</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haupt, Fabian</au><au>Berding, Georg</au><au>Namazian, Ali</au><au>Wilke, Florian</au><au>Böker, Alena</au><au>Merseburger, Axel</au><au>Geworski, Lilli</au><au>Kuczyk, Markus Antonius</au><au>Bengel, Frank Michael</au><au>Peters, Inga</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Ther</stitle><addtitle>Adv Ther</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>34</volume><issue>4</issue><spage>986</spage><epage>994</epage><pages>986-994</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Introduction
The bone scan index (BSI) was introduced as a quantitative tool for tumor involvement in bone of patients with metastatic prostate cancer (mPCa). The computer-aided diagnosis device for BSI analysis EXINIbone
BSI
seems to represent technical progress for the quantitative assessment of bone involvement. But it is not yet clear if the automated BSI (aBSI) could contribute to improved evaluation of progression in patients under antiandrogens or chemotherapy in contrast to the visual interpretation and/or conventional biomarkers such as the prostate-specific antigen (PSA).
Methods
In 49 mPCa patients, bone scans were performed initially and during different therapy courses. Scans were evaluated visually and by the artificial-neural-network-based expert system EXINIbone
BSI
. Progression of metastatic bone involvement was defined according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria in the visual interpretation. The computer-assisted interpretation was based on different cutoff values in relative changes of the aBSI. Additionally, assessments according to bone scanning were compared to changes in the PSA value as a potential surrogate for treatment response.
Results
Using a sensitive cutoff value (5% or 10%) for the relative aBSI increase led to significantly increased progression determination compared to the visual interpretation of bone scans (49% and 43% vs. 27%,
p
< 0.001). In 63% of the cases PSA and BSI changes matched, whereas in 18% progression was only indicated by the aBSI. A relative cutoff of 5% for the aBSI decrease could reclassify 47 serial scan pairs which were visually interpreted as stable into 22 progressive and 25 remissive scans.
Conclusion
Distinct thresholds of the relative aBSI could help to better assess disease progression in mPCa patients. Manual corrections of the BSI values are not required in most cases. The aBSI could serve as a useful additional parameter for therapy monitoring in mPCa patients in the future.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>28265811</pmid><doi>10.1007/s12325-017-0505-z</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2401-922X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0741-238X |
| ispartof | Advances in therapy, 2017-04, Vol.34 (4), p.986-994 |
| issn | 0741-238X 1865-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1875142223 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Aged Bone Neoplasms - diagnostic imaging Bone Neoplasms - secondary Cardiology Disease Progression Endocrinology Expert Systems Health technology assessment Humans Internal Medicine Male Medicine Medicine & Public Health Middle Aged Oncology Original Research Pharmacology/Toxicology Prognosis Prostatic Neoplasms - pathology Radionuclide Imaging Retrospective Studies Rheumatology |
| title | Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A41%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expert%20System%20for%20Bone%20Scan%20Interpretation%20Improves%20Progression%20Assessment%20in%20Bone%20Metastatic%20Prostate%20Cancer&rft.jtitle=Advances%20in%20therapy&rft.au=Haupt,%20Fabian&rft.date=2017-04-01&rft.volume=34&rft.issue=4&rft.spage=986&rft.epage=994&rft.pages=986-994&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-017-0505-z&rft_dat=%3Cproquest_cross%3E1875142223%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1875142223&rft_id=info:pmid/28265811&rfr_iscdi=true |